Concurrent administration of trastuzumab and anthracyclines as adjuvant regimen for HER2-positive breast cancer: a randomised controlled trial

BACKGROUND: The regimen of concurrent administration of trastuzumab and anthracyclines in the adjuvant treatment of breast cancer has never been evaluated prospectively for fear of cardiac toxicity. METHODS: Patients with HER2-positive operable breast cancer were randomised to receive adjuvant treat...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Shen, Songjie, Xu, Ying, Zhou, Yidong, Mao, Feng, Guan, Jinghong, Sun, Qiang
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2017
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5696221/
https://ncbi.nlm.nih.gov/pubmed/29190955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21579
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky